newsfilter
← Latest News
GlobeNewswire·

Turning Point Therapeutics Announces Positive Topline Data by Blinded Independent Central Review for Repotrectinib Across All ROS1-Positive NSCLC Cohorts of Phase 1/2 TRIDENT-1 Study

In a total of 71 TKI-naïve patients, confirmed objective response rate (cORR) of 79% (95% CI: 68, 88) In the TKI-naïve population with approximately 10 months of follow-up, initial estimated durability of response and progression free survival of 85%